CNPR Market Analysis 4 — Questions and Answers
Question 1: What does 'pull-through' mean in the context of pharmaceutical market access?
- A tactic for increasing brand awareness with patients
- Converting formulary wins into actual prescriptions at the pharmacy and physician level (Correct answer)
- Pulling competitor samples from physician offices
- Accelerating drug through the FDA pipeline
Correct answer: Converting formulary wins into actual prescriptions at the pharmacy and physician level
Pull-through refers to the sales activities needed to translate formulary coverage into actual prescription volume at the prescriber and dispenser level.
Question 2: Which metric measures the percentage of a product's prescriptions that are actually dispensed relative to the number written?
- Market share index
- Prescription-to-dispense rate (abandonment rate) (Correct answer)
- Formulary compliance ratio
- Total prescription days
Correct answer: Prescription-to-dispense rate (abandonment rate)
The prescription-to-dispense (or abandonment) rate tracks how many written prescriptions are actually filled, revealing access or affordability barriers.
Question 3: A competitor drug receives a new FDA-approved indication in your primary therapeutic area. In SWOT terms, this represents:
- A weakness for your brand
- An internal strength to leverage
- An external threat to your market position (Correct answer)
- An opportunity for co-promotion
Correct answer: An external threat to your market position
A competitor gaining a new indication in your market is an external environmental threat that may take market share from your product.
Question 4: In pharmaceutical market analysis, 'patient compliance' data is important primarily because:
- It determines which sales reps are promoted
- It reflects real-world treatment effectiveness and impacts refill prescription volumes (Correct answer)
- It is required for FDA reporting purposes
- It dictates product pricing strategies
Correct answer: It reflects real-world treatment effectiveness and impacts refill prescription volumes
Patient compliance (adherence) directly affects clinical outcomes and drives refill prescriptions, which are a major component of total prescription volume.
Question 5: What does 'category growth rate' tell a pharmaceutical sales rep about her market?
- How fast her specific brand is growing
- The rate at which the entire drug class is expanding or contracting (Correct answer)
- The speed of FDA approvals in a therapeutic area
- The rate of new competitor product launches
Correct answer: The rate at which the entire drug class is expanding or contracting
Category growth rate measures how fast the overall therapeutic class is growing, providing context for interpreting individual brand performance.
Question 6: A physician who was previously in decile 8 has dropped to decile 3 in your product's prescriptions. What is the most likely appropriate action?
- Remove the physician from your call list
- Investigate the reason for the decline and address any barriers (Correct answer)
- Increase sample drops to the office
- Escalate to managed care team immediately
Correct answer: Investigate the reason for the decline and address any barriers
A significant drop in prescribing warrants investigation — possible causes include formulary change, patient adverse event, or a competitor detail — before taking action.
Question 7: Which of the following best describes 'off-invoice discounts' in pharmaceutical market analysis?
- Price reductions offered directly to patients at the pharmacy
- Discounts given to wholesalers or payers that are not reflected on the published list price (Correct answer)
- Charitable drug donation programs
- Co-pay assistance card programs
Correct answer: Discounts given to wholesalers or payers that are not reflected on the published list price
Off-invoice discounts are price concessions negotiated with channel partners (wholesalers, PBMs) that reduce the effective net price below the WAC list price.
CNPR Market Analysis 4
What does 'pull-through' mean in the context of pharmaceutical market access?